Tevogen Bio Holdings Inc. (TVGNW) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$0.05

From 52W high−5.37%

Volume210492.00

Market cap$16.23M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataNov 4, 2026

Open

$0.05

From 52W high

−5.37%

Volume

210492.00

Market cap

$16.23M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−1.0x

P/E (TTM)

—

RSI (14)

59.9

MomentumView details →

1D Return

+7.95%

YTD Return

+97.63%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−1.0x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

−1.8x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

243.15%

ROA (TTM)

−457.14%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+36.07%

FCF YoY

+12.85%

Revenue CAGR 3Y

—

EPS CAGR 3Y

−72.65%

EBITDA YoY

+31.99%

MomentumView details →

1D Return

+7.95%

YTD Return

+97.63%

1Y Return

+67.81%

RSI (14)

59.9

vs 50D SMA

+32.55%

vs 200D SMA

+74.21%

Capital & dividendView details →

Debt/Equity

−0.34x

Current Ratio

0.33x

Quick Ratio

0.33x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$1.52

EPS Surprise

40.04%

Beats (12Q)

4/12

Next Q EPS Est

−$2.41

Avg Surprise (4Q)

32.75%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−21.61M

Op. CF (TTM)

−11.57M

Next earningsNov 24, 2026 →

Latest newsMore news →

Tevogen Bio Holdings Inc. granted CEO Ryan Saadi a restricted stock award covering 50,000,000 common shares, vesting only if the company achieves $1.0 billion in aggregate revenue by December 31, 2031.1d ago

Tevogen signed a non-exclusive, non-binding letter of intent to evaluate a potential acquisition of HRK Healthcare LLC.27d ago

Similar companies

Acumen Pharmaceuticals, Inc.ABOS Jasper Therapeutics, Inc.JSPR Pluri Inc.PLUR Pasithea Therapeutics Corp.KTTA Marker Therapeutics, Inc.MRKR Hoth Therapeutics, Inc.HOTH Find similar companies →

Latest newsMore news →

Tevogen Bio Holdings Inc. granted CEO Ryan Saadi a restricted stock award covering 50,000,000 common shares, vesting only if the company achieves $1.0 billion in aggregate revenue by December 31, 2031.1d ago Tevogen signed a non-exclusive, non-binding letter of intent to evaluate a potential acquisition of HRK Healthcare LLC.27d ago